The American Professional Society of ADHD and Related Disorders

Singh presented during the recent APSARD conference. onthe topic of ADHD and bipolar disorder.

Crosbie presented results from a small pilot study testing a video game platform for patients with executive function deficits during the annual APSARD meeting.

Dr. Matthew Brams presented new data showing the efficacy of CTx-1301 for ADHD.

CTx-1301's formulation enables 3 different doses within 1 pill for ADHD.

Researchers are prepared a phase 3 trial testing the treatment in adults with ADHD.

The role of many in psychiatry has changed during the COVID-19 pandemic.

Such scores could provide insight into the significant comorbidity rate of ADHD and other youth mood and emotional dysregulation issues.

Personalized, daily self-reporting for patients could influence future therapeutic strategies.

Randomized controlled trials are needed to evaluate their efficacy in comparison with in-person group meetings.

A pair of researchers present plans to improve collaboration with other professionals in ADHD.

The likelihood of smoking addiction is associated with traits also closely associated with worsened ADHD.

An ADHD coach can work on more goal-based plans for individuals with ADHD.

A study finds that secondhand smoking may have a greater negative impact on children than prenatal smoke exposure.

There is a high association between parents' concerns of autism spectrum disorder in their children and identified symptoms of ADHD.

There is currently no approved treatment for fragile X syndrome.

Current estimates indicate that non-adherence to stimulants is as high as 87%.

New research expands on the understood link between sleep and ADHD-related behavior, and gives clinicians new therapeutic targets.

Though the correlation is concerning for at-risk groups, experts believe it could inform individualized psychiatric care during crises.

The APSARD study finds that most neuropsychological assessment scores did not differ significantly between both in-person and virtual visit modalities.

Methylphenidate has shown promising boosting morning function in pediatric patients with ADHD.

Both monotherapy and combination of the unique regimen was shown to improve manic and depressive status at 12 weeks.

The Child Behavior Checklist may provide invaluable information to clinicians regarding the type and severity of comorbid psychopathologies.

The treatment improves morning function for adolescent ADHD patients.

Dr. David Goodman predicts some patients may improve their organizational skills during the pandemic.

Adults with ADHD may face a number of challenges during the ongoing pandemic.

The virtual conference will feature researchers from the US, Germany, Japan, and more.